Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2020 - 06 - 05

Menarini invests 150 million euros in a new pharmaceutical plant in Italy

Its name will be linked to the relaunch of the country

Lucia and Alberto Giovanni Aleotti: “A heartfelt choice for our country”


Menarini chooses Italy for its new €150 million manufacturing site.

Not only will the new plant be the most modern and among the largest of the Group, but it will also be a sign of Italy’s strong desire to relaunch itself. The decision to interrupt the search for the most economically attractive international location and the choice to favour Italy matured during the extremely difficult period of the lockdown, when the tragic consequences of the pandemic on the Italian economy began to be evident. “Together with the Board of Directors we made a decision with our hearts: to favour our country, and to do it with an investment of €150 million that would immediately contribute to the economy and to employment,” commented Lucia and Alberto Giovanni Aleotti, shareholders and members of the Menarini Board. “We are an Italian company and we are proud to be one.  Here we will manufacture drugs which are the essence of the Menarini Group and are used every day by tens of millions of patients in Italy and abroad.

The site will be built near Florence, it will cover a total area of 40,000 square meters and employ 250 people and just as many in the satellite activities.  It will be a smart manufacturing plant with innovative production technologies and automation and digitalization systems in line with the Industry 4.0 program including important environmental sustainability objectives.

The plant will have an annual production capacity of about 100 million packs corresponding to about 3 billion tablets and will be imprinted with that same desire for relaunching the country which gave it life thanks to a particular initiative: “This manufacturing site will be given its name much as with a new baby,” continue Lucia and Alberto Giovanni Aleotti.  “It will be our employees who will choose it.  A name that embodies the courage, the will and the heart of an Italy that wants to get back on its feet and unite in the most difficult moments.



The Menarini Group, which has recently announced the tender offer of the US biotech company, Stemline, closed 2019 with growing figures compared to 2018.

Turnover reaches nearly € 3 billion 800 million (€3,793 million), with an increase of 3.2% compared to 2018, and an EBITDA of €492 million.  Growth was driven by international markets despite the patent expiration of Adenuric (febuxostat), a drug for hyperuricemia.

"The year that ended was obviously not affected by the Covid-19 crisis and saw Menarini increase its presence abroad and strengthen its governance with the appointment in September of the Group’s CEO, Elcin Barker Ergun.  Today international turnover makes up 77% of the total one thanks to the dedication and commitment of our employees who are the ambassadors of quality of all Menarini drugs worldwide." commented Eric Cornut, Chairman of the Menarini Group.